Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTiST - Aromasin Randomised Trial +/- Sutent as Neoadjuvant Therapy for Post-menopausal Women with Breast Cancer
2008-006161-84Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer and Infiltrating Ductal Carcinoma (IDC) comparing Exemestane alone (Aromasin) with Exemestane plus sunitinib (Aromasin + Sutent) (2 arms). Primary endpoint: Ki67 response to therapy. Started Apr 2009; status: terminated.
02
Drugs
sunitinibexemestane
03
Conditions
breast cancerInfiltrating Ductal Carcinoma (IDC)
Beyond the preview
Go deeper on 2008-006161-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006161-84.